CAMS Q4 profit rises. But the stock's stuck in reverse

A solid quarter, but the market wasn't impressed. CAMS , the back-office brain behind India's mutual fund industry, posted a decent Q4—net profit rose 10% to Rs 114 crore, and revenues were up nearly 15% to Rs 356 crore. It even announced a sweet Rs 19-per-share dividend.

But the stock? It fell nearly 3% on May 6, trading currently at Rs 3,732 on the BSE.

For a company that powers 68% of India's mutual fund transactions, this isn't about the headline numbers. It's about what's brewing underneath.

What's going on?

The earnings weren't bad. CAMS continues to dominate the MF registrar space, servicing 26 out of 51 AMCs. Its core business remains sticky, and it's making progress outside mutual funds too, with non-MF revenue now forming nearly 14% of the pie.

But costs are rising faster than revenue. Operating margins slipped 120 basis points to 44.9%, and total expenses jumped over 18% year-on-year. That's what's got investors edgy.

And in a market that's quick to punish even the hint of a slowdown, that margin dip hit sentiment hard.

Why it matters

CAMS' stock has already lost nearly 30% from its 52-week high of Rs 5,367. And even though it's off the lows of Rs 3,030, the bounce hasn't been convincing. Add to that the broader volatility in financial services stocks, and it's clear why investors are staying cautious.

Some brokerages still see potential. Vaishali Parekh of Prabhudas Lilladher has a buy call with a target of Rs 3,600. But most are in 'wait and watch' mode, looking for signs that margins will stabilise.

Value Research Online Ratings

Value Research Stock Rating gives CAMS an overall rating of 5 stars out of 5. The company's specific scores are as follows:

• Quality Score: 10/10
  
• Growth Score: 7/10
  
• Valuation Score: 4/10
  
• Momentum Score: 6/10

Quick comparison: CAMS vs KFin Tech

Final word

CAMS did what it needed to—delivered stable numbers and maintained its MF monopoly. But markets aren't feeling generous unless you overdeliver. Until costs are reined in, the stock may continue to feel the heat.

If you're a long-term investor, CAMS still checks a lot of boxes—dominant market share, strong financials, and a steady dividend. But this isn't a fast-growth story anymore. It's a steady compounder, and it'll move with the pace of mutual fund inflows and industry reforms.

Disclaimer: This story was created with the assistance of artificial intelligence and is intended for informational purposes only. Please take it with a pinch of salt and do your own research or consult a financial advisor before making investment decisions.